Paraguay Medical Device Registration 2026: Registro Publico de Poderes and the Two-Year Validity Rule
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
- Article 6 inc. b) requires that the power of attorney or distribution and sales authorization letter be registered in the Registro Público de Poderes (Public Registry of Powers of Attorney). Registration is a separate legal requirement: it is not satisfied by signature alone, and it is not satisfied by notarization alone.
- Validity rule: where the document does not expressly state a validity period, it is counted as valid for 2 years from the date of issuance. The rule is automatic and applies without any need for the authority to make a finding.
- The same rule applies to the free sale certificate (Article 6 inc. d)) — the two documents follow an identical validity-management logic, so one tracking process can cover both.
- Article 12 inc. h): at renewal, the importer must submit again the power of attorney and the free sale certificate, meaning these two documents are a recurring obligation that returns every 10 years with the renewal filing, and must be valid at that moment.
2. Legal basis
| Regulation | Number / reference | Date | Provisions |
|---|---|---|---|
| Resolution establishing the requirements for marketing authorization of medical devices | Resolución DINAVISA N° 226/2024 | 2024-08-27; Article 36 in force as of 2024-09-16 | Article 6 inc. b) and inc. d); Article 12 inc. h) |
| Operational instructions and guide for submitting applications | Instructivo ITR–DGRS-002, Versión 02 | 2024-09-09 | Article 8 (documents must be valid at issuance/NSO) |
The two instruments work together: Resolución DINAVISA N° 226/2024 defines which documents are required and their default validity, while the Instructivo sets when those documents must be valid within the assessment timeline. A filing strategy that ignores the Instructivo timing rule can produce dossiers that are complete on the day of submission yet defective on the day of decision.
The interaction of the two validity regimes also has an asymmetric effect on renewals. At first registration the applicant controls the issuance calendar and can renew documents before filing; at renewal, the dossier under Article 12 inc. h) must present a power of attorney and a free sale certificate that are valid at the moment of filing and are expected to remain valid through the assessment. Because the renewal date is fixed by the expiry of the existing 10-year certificate, the document refresh has to be scheduled backward from that date with enough lead time for manufacturer signatures, legalization, and registry registration. Companies that discover this at the renewal window rather than a year earlier routinely face compressed timelines and, in the worst case, a renewal filed with documents already past their default validity.
3. Expert insights
Insight one: registration is an independent requirement and cannot substitute for, or be substituted by, signature. An authorization letter that is signed but not registered does not meet the wording of Article 6 inc. b). Together with the exclusion of letters issued by distributors, this forms a two-gate threshold for holding the license: the authority looks both at who issued the letter and at whether it has been registered. Companies converting from another market template should build the registry step into the document workflow, with an owner and a deadline, because it is the step most often left to the local party and most often discovered missing late.
Insight two: the 2-year rule turns a long-term authorization into an asset that requires maintenance. Both the authorization letter and the free sale certificate (CLV) are subject to the 2-year default where no period is stated. The certificate itself is valid for 10 years, which means both documents must be refreshed several times during a single holding period; otherwise a gap appears at the renewal milestone. Keeping the expiry dates of both documents in a single maintenance calendar, reviewed quarterly, is the most economical way to prevent a renewal-stage defect that cannot be cured quickly.
Insight three: Article 8 of the Instructivo requires validity at issuance, not only at submission. The Instructivo states that all documents required by the resolution must be in force when the registration certificate or NSO is issued, calculated against the assessment timeline. For the comprehensive analysis pathway (120 working days), a 2-year margin at submission does not necessarily cover the period up to the issuance date (practical estimate: an inference drawn from the structure of the provisions). Applicants using slower pathways, or facing multiple rounds of clarifications, should renew the documents proactively rather than defend an expiring letter.
4. Practical recommendations
- Place the expiry dates of the authorization letter and the CLV in a single document-validity maintenance table and work backward from the expected issuance date of the certificate.
- State the validity period of the authorization letter expressly (recommended to cover the expected issuance date plus a buffer) so the 2-year default rule does not apply.
- After completing the registry registration, retain the registration evidence and archive it together with the original authorization letter, so the priority-ranking position can be proven years later.
- Reserve a dedicated line for Article 12 inc. h) in the renewal schedule and begin preparing updated versions of both documents well before the renewal window opens.
- Assign clear internal ownership for the document-validity calendar — ideally the regulatory function rather than the distributor — and review it on a fixed cadence, so that the expiry of a manufacturer-issued letter is never discovered by the local party after the document has already lapsed.
- Archive the registry registration evidence under a defined document-control code with the original letter, so the file can be reconstructed years later if the priority position is ever challenged by a competing applicant.
5. Verification checklist
- □ Authorization letter registered in the Registro Público de Poderes with evidence retained
- □ Validity period of the letter expressly stated or managed under the 2-year rule
- □ CLV and authorization letter validity managed on a combined calendar
- □ Document validity back-calculated from the expected issuance date (Article 8)
- □ Renewal schedule includes the item under Article 12 inc. h)
Regulatory information verified as of October 29, 2026.
GRZAN provides medical device registration support in Paraguay for manufacturers, importers, and authorized representatives, covering registry registration, document validity management, and renewal planning. Contact info@grzanglobal.com for tailored guidance on this topic.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us